Entrada doses first participant in Phase 1 trial of ENTR-601-44 for Duchenne MD

Entrada Therapeutics, Inc.

First participant dosed in Phase 1 trial of ENTR-601-44 for DMD patients amenable to exon 44 skipping.
Trial conducted in UK; targets ~40 healthy male volunteers; endpoints include safety, PK, and target engagement.
Data from the Phase 1 trial expected in the second half of 2024.
Initiation marks Entrada's transition into a clinical-stage company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.